Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SV BR 1 GM cancer vaccine - BriaCell Therapeutics

Next Previous
Drug Profile

SV BR 1 GM cancer vaccine - BriaCell Therapeutics

Alternative Names: Allogeneic GM CSF secreting breast cancer vaccine - BriaCell Therapeutics; Bria-IMT™; BriaVax; GM CSF gene-transfected breast cancer vaccine - BriaCell Therapeutics; SV-BR-1 breast cancer cell line vaccine - BriaCell Therapeutics; SV-BR-1-GM; SV-BR-1-GM-vaccine-BriaCell-Therapeutics; SV-BR1-GM-breast-cancer-vaccine-BriaCell-Therapeutics

Latest Information Update: 18 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wiseman Research Initiatives LLC
  • Developer BriaCell Therapeutics Corp
  • Class Antineoplastics; Cancer vaccines; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer
  • No development reported Ovarian cancer

Most Recent Events

  • 14 Sep 2026 Data Safety Monitoring Board (DSMB) grants positive recommendation for phase III study of SV BR 1 GM cancer vaccine in Breast cancer
  • 02 Jun 2026 Efficacy and pharmacodynamics data from a phase I/II trial in Breast cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO 2026)
  • 22 Apr 2026 Updated efficacy and adverse events data from a phase III Bria-ABC trial in Breast cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top